Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription 17.10.2022 1 Am J Surg 1 Ann Oncol 3 Ann Surg 18 Ann Surg Oncol 4 BMC Cancer 3 Br J Cancer 1 Breast Cancer 2 Breast Cancer (Dove Med Press) 2 Breast Cancer Res 9 Breast Cancer Res Treat 3 Cancer 1 Cancer Chemother Pharmacol 2 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 3 Cancer Res 2 Clin Breast Cancer 1 Clin Cancer Res 1 Exp Cell Res 1 Histopathology 1 Int J Cancer 1 Int J Oncol 4 J Natl Cancer Inst 4 J Surg Oncol 2 Lancet Oncol 3 N Engl J Med 1 NPJ Breast Cancer 5 PLoS One 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg

1. SINGH R, Cao L, Sarode AL, Kharouta M, et al
   Trends in surgery and survival for T1-T2 male breast cancer: A study from the National Cancer Database.
   Am J Surg. 2022 Sep 25. pii: S0002-9610(22)00592.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. GEYER CE JR, Garber JE, Gelber RD, Yothers G, et al
   Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
   Ann Oncol. 2022 Oct 10. pii: S0923-7534(22)04165.
   PubMed         Abstract available
   
   

   
   Ann Surg

3. GRANOFF MD, Johnson AR, Shillue K, Fleishman A, et al
   A Single Institution Multi-disciplinary Approach to Power-assisted Liposuction for the Management of Lymphedema.
   Ann Surg. 2022;276:e613-e621.
   PubMed         Abstract available
   
   
4. KUEMMEL S, Heil J, Rueland A, Seiberling C, et al
   A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
   Ann Surg. 2022;276:e553-e562.
   PubMed         Abstract available
   
   
5. MARTELLI G, Barretta F, Miceli R, Folli S, et al
   Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study.
   Ann Surg. 2022;276:e544-e552.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. KIM YS, Cho HG, Kim J, Park SJ, et al
   ASO Author Reflections: Prediction of Implant Size Based on Breast Volumetry Using Mammography and Breast MRI in DTI Breast Reconstruction.
   Ann Surg Oncol. 2022;29:7855-7856.
   PubMed        
   
   
7. KIM YS, Cho HG, Kim J, Park SJ, et al
   Prediction of Implant Size Based on Breast Volume Using Mammography with Fully Automated Measurements and Breast MRI.
   Ann Surg Oncol. 2022;29:7845-7854.
   PubMed         Abstract available
   
   
8. PILTIN MA, Hoskin TL, Day CN, Habermann EB, et al
   Overuse of Axillary Surgery in Patients with Ductal Carcinoma In Situ: Opportunity for De-escalation.
   Ann Surg Oncol. 2022;29:7705-7712.
   PubMed         Abstract available
   
   
9. ABEL MK, Mukhtar RA
   ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
   Ann Surg Oncol. 2022;29:7748-7749.
   PubMed        
   
   
10. PESTANA CV, Livasy CA, Donahue EE, Neelands B, et al
    Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?
    Ann Surg Oncol. 2022;29:7716-7724.
    PubMed         Abstract available
    
    
11. OLSEN MA, Myckatyn TM, Lee CN
    ASO Author Reflections: Need for Individualized Risk Prediction to Facilitate Shared Decision Making in Post-mastectomy Breast Reconstruction.
    Ann Surg Oncol. 2022;29:7765-7766.
    PubMed        
    
    
12. NICKEL KB, Myckatyn TM, Lee CN, Fraser VJ, et al
    Individualized Risk Prediction Tool for Serious Wound Complications After Mastectomy With and Without Immediate Reconstruction.
    Ann Surg Oncol. 2022;29:7751-7764.
    PubMed         Abstract available
    
    
13. NICKEL KB, Myckatyn TM, Lee CN, Fraser VJ, et al
    ASO Visual Abstract: Individualized Risk Prediction Tool for Serious Wound Complications after Mastectomy with and without Immediate Reconstruction.
    Ann Surg Oncol. 2022;29:7767-7768.
    PubMed        
    
    
14. KIM YS, Cho HG, Kim J, Park SJ, et al
    ASO Visual Abstract: Prediction of Implant Size Based on Breast Volume Using Mammography with Fully Automated Measurement and Breast MRI.
    Ann Surg Oncol. 2022;29:7857-7858.
    PubMed        
    
    
15. PILTIN MA, Hoskin TL, Day CN, Habermann EB, et al
    ASO Visual Abstract: Overuse of Axillary Surgery for Patients With Ductal Carcinoma In Situ: Opportunity for De-Escalation.
    Ann Surg Oncol. 2022;29:7715.
    PubMed        
    
    
16. FAN B, James T
    Avoiding Axillary Management Pitfalls After Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2022;29:7265-7266.
    PubMed        
    
    
17. PESTANA CV, Livasy CA, Donahue EE, Neelands B, et al
    ASO Visual Abstract: Does Residual Cancer Burden Predict Local Recurrence after Neoadjuvant Chemotherapy?
    Ann Surg Oncol. 2022;29:7725.
    PubMed        
    
    
18. PALMQUIST E, Limberg J, Chu JJ, White C, et al
    ASO Visual Abstract: Patient-Reported Outcome Measures in Patients with Clinical T4 Breast Cancer Treated with Mastectomy With and Without Reconstruction.
    Ann Surg Oncol. 2022 Oct 7. pii: 10.1245/s10434-022-12585.
    PubMed         Abstract available
    
    
19. SAHA D, Balasubramanian A, Kannan A, Pant A, et al
    Breast Cancer Screening in Young Women with the Advent of Newer Techniques: Current Evidence and Future Considerations.
    Ann Surg Oncol. 2022 Oct 8. pii: 10.1245/s10434-022-12550.
    PubMed        
    
    
20. MURPHY BL, Yi M, Barrera AG, Tripathy D, et al
    ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
    Ann Surg Oncol. 2022 Oct 10. pii: 10.1245/s10434-022-12519.
    PubMed        
    
    
21. HASSAN AM, Offodile AC 2nd
    ASO Author Reflections: Neighborhood-Level Deprivation Impacts Patient-Reported Outcomes Following Breast Cancer Surgery.
    Ann Surg Oncol. 2022 Oct 10. pii: 10.1245/s10434-022-12521.
    PubMed        
    
    
22. KNAPE N, Park JH, Agala CB, Spanheimer P, et al
    Can We Forgo Sentinel Lymph Node Biopsy in Women Aged >/= 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
    Ann Surg Oncol. 2022 Oct 10. pii: 10.1245/s10434-022-12626.
    PubMed         Abstract available
    
    
23. POSTLEWAIT LM
    Assessment of Novel Therapeutics for Individualized Breast Cancer Care in the Modern Era: The Role of Metformin in Breast Cancer Therapy.
    Ann Surg Oncol. 2022 Oct 12. pii: 10.1245/s10434-022-12627.
    PubMed        
    
    

    
    BMC Cancer

24. HAWKINS R, McWilliams L, Ulph F, Evans DG, et al
    Healthcare professionals' views following implementation of risk stratification into a national breast cancer screening programme.
    BMC Cancer. 2022;22:1058.
    PubMed         Abstract available
    
    
25. ZHANG J, Dong D, Wei Q, Ren L, et al
    CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma.
    BMC Cancer. 2022;22:1052.
    PubMed         Abstract available
    
    
26. WONG CHONG E, Joncas FH, Seidah NG, Calon F, et al
    Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
    BMC Cancer. 2022;22:1049.
    PubMed         Abstract available
    
    
27. DI BENEDETTO C, Oh J, Choudhery Z, Shi W, et al
    NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer.
    BMC Cancer. 2022;22:1056.
    PubMed         Abstract available
    
    

    
    Br J Cancer

28. TRAN TV, Rubino C, Allodji R, Andruccioli M, et al
    Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
    Br J Cancer. 2022 Oct 12. pii: 10.1038/s41416-022-01982.
    PubMed         Abstract available
    
    
29. ZHANG M, Wang J, Jin Y, Zheng Q, et al
    YTHDF2-mediated FGF14-AS2 decay promotes osteolytic metastasis of breast cancer by enhancing RUNX2 mRNA translation.
    Br J Cancer. 2022 Oct 10. pii: 10.1038/s41416-022-02006.
    PubMed         Abstract available
    
    
30. JACOT W, Lusque A, Vicier C, Mailliez A, et al
    Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
    Br J Cancer. 2022 Oct 7. pii: 10.1038/s41416-022-02003.
    PubMed         Abstract available
    
    

    
    Breast Cancer

31. MAVROPALIAS G, Cormie P, Peddle-McIntyre CJ, Galvao DA, et al
    The effects of home-based exercise therapy for breast cancer-related fatigue induced by radical radiotherapy.
    Breast Cancer. 2022 Oct 14. pii: 10.1007/s12282-022-01408.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

32. GAO C, Li L, Jin X, Song X, et al
    The Involvement of Insulin-Like Growth Factor 2 Messenger Ribonucleic Acid-Binding Protein 2 in the Regulation of the Expression of Breast Cancer-Related Genes.
    Breast Cancer (Dove Med Press). 2022;14:311-322.
    PubMed         Abstract available
    
    
33. ALSUMAI TS, Alhazzaa N, Alshamrani A, Assiri S, et al
    Factors Predicting Positive Sentinel Lymph Node Biopsy in Clinically Node-Negative Breast Cancer.
    Breast Cancer (Dove Med Press). 2022;14:323-334.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

34. NOUNU A, Kar SP, Relton CL, Richmond RC, et al
    Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
    Breast Cancer Res. 2022;24:66.
    PubMed         Abstract available
    
    
35. ONAGI H, Horimoto Y, Sakaguchi A, Ikarashi D, et al
    High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
    Breast Cancer Res. 2022;24:67.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

36. ZHENG Q, Luo H, Xia W, Lu Q, et al
    Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study.
    Breast Cancer Res Treat. 2022 Oct 7. pii: 10.1007/s10549-022-06746.
    PubMed         Abstract available
    
    
37. LEVY J, Farag F, Cole J
    Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience.
    Breast Cancer Res Treat. 2022;196:207-213.
    PubMed         Abstract available
    
    
38. GAO W, Lu S, Zeng Y, Chen X, et al
    Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis.
    Breast Cancer Res Treat. 2022;196:129-141.
    PubMed         Abstract available
    
    
39. HASSING CMS, Mejdahl MK, Laenkholm AV, Kroman N, et al
    Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors
    Breast Cancer Res Treat. 2022;196:197-206.
    PubMed         Abstract available
    
    
40. QU FL, Lin CJ, Liu ZB, Cao AY, et al
    Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
    Breast Cancer Res Treat. 2022;196:97-109.
    PubMed         Abstract available
    
    
41. LOSURDO A, Lisa AVE, Tomatis M, Ponti A, et al
    Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience.
    Breast Cancer Res Treat. 2022;196:87-95.
    PubMed         Abstract available
    
    
42. BROWN L, Naffouje SA, Sam C, Laronga C, et al
    Neoadjuvant systemic therapy in geriatric breast cancer patients: a National Cancer Database (NCDB) analysis.
    Breast Cancer Res Treat. 2022 Oct 8. pii: 10.1007/s10549-022-06751.
    PubMed         Abstract available
    
    
43. MORENO GA, Molina MI, Eastwood D, Auer PL, et al
    Contemporary evaluation of estrogen receptor and progesterone receptor expression in breast cancer-associated stroma.
    Breast Cancer Res Treat. 2022 Oct 8. pii: 10.1007/s10549-022-06754.
    PubMed         Abstract available
    
    
44. FREEDMAN RA, Ko NY, Lederman RI, Gagnon H, et al
    Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors.
    Breast Cancer Res Treat. 2022 Oct 11. pii: 10.1007/s10549-022-06752.
    PubMed         Abstract available
    
    

    
    Cancer

45. REN Y, Kebede MA, Ogunleye AA, Emerson MA, et al
    Burden of lymphedema in long-term breast cancer survivors by race and age.
    Cancer. 2022 Oct 12. doi: 10.1002/cncr.34489.
    PubMed         Abstract available
    
    
46. WARREN LEG, Niman SM, Remolano MC, Landry JM, et al
    Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer.
    Cancer. 2022 Oct 10. doi: 10.1002/cncr.34441.
    PubMed         Abstract available
    
    
47. DHAKAL A, Anders CK
    Screening brain MRI in inflammatory breast cancer: Is it time?
    Cancer. 2022 Oct 10. doi: 10.1002/cncr.34442.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

48. PROCTOR JR, Gartner EM, Gray TE, Davies RH, et al
    Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
    Cancer Chemother Pharmacol. 2022;90:399-408.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

49. HVIDTFELDT UA, Chen J, Rodopoulou S, Strak M, et al
    Breast cancer incidence in relation to long-term low-level exposure to air pollution in the ELAPSE pooled cohort.
    Cancer Epidemiol Biomarkers Prev. 2022 Oct 10. pii: 709688.
    PubMed         Abstract available
    
    
50. ASHI K, Ndom P, Gakwaya A, Makumbi T, et al
    Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda.
    Cancer Epidemiol Biomarkers Prev. 2022 Oct 10. pii: 709687.
    PubMed         Abstract available
    
    

    
    Cancer Lett

51. XIE XF, Wu NQ, Wu JF, Zhang GL, et al
    CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
    Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944.
    PubMed         Abstract available
    
    

    
    Cancer Res

52. DURO-SANCHEZ S, Nadal-Serrano M, Lalinde-Gutierrez M, Arenas EJ, et al
    Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709715. doi: 10.1158/0008-5472.CAN-22-0787.
    PubMed         Abstract available
    
    
53. HONG J, Lee JH, Zhang Z, Wu Y, et al
    PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer.
    Cancer Res. 2022 Oct 12. pii: 709714. doi: 10.1158/0008-5472.CAN-22-0736.
    PubMed         Abstract available
    
    
54. ELKHOLI IE, Lalonde A, Park M, Cote JF, et al
    Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s).
    Cancer Res. 2022 Oct 10. pii: 709673. doi: 10.1158/0008-5472.CAN-22-1902.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

55. SINGH J, Sangwan N, Chauhan A, Avti PK, et al
    Integrative Expression, Survival Analysis and Cellular miR-2909 Molecular Interplay in MRN Complex Check Point Sensor Genes (MRN-CSG) Involved in Breast Cancer.
    Clin Breast Cancer. 2022 Sep 9. pii: S1526-8209(22)00192.
    PubMed         Abstract available
    
    
56. HENDRIX N, Oestreicher N, Lalla D, Dolan CM, et al
    Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model.
    Clin Breast Cancer. 2022 Sep 1. pii: S1526-8209(22)00189.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

57. TSUJI J, Li T, Grinshpun A, Coorens T, et al
    Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Hormone Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2022 Oct 10. pii: 709684. doi: 10.1158/1078-0432.CCR-22-2305.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

58. JIN Y, Cai W, Zhao C, Yang F, et al
    EMT status of circulating breast cancer cells and impact of fluidic shear stress.
    Exp Cell Res. 2022 Oct 10:113385. doi: 10.1016/j.yexcr.2022.113385.
    PubMed         Abstract available
    
    

    
    Histopathology

59. XU B, Viswanathan K, Umrau K, Al-Ameri TAD, et al
    Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.
    Histopathology. 2022;81:670-679.
    PubMed         Abstract available
    
    

    
    Int J Cancer

60. LYNGE E, Vjeborg I, Lillholm M, Nielsen M, et al
    Breast Density and Risk of Breast Cancer.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34316.
    PubMed         Abstract available
    
    

    
    Int J Oncol

61. ZHANG Y, Liang Y, Wang Y, Ye F, et al
    A novel ferroptosisrelated gene signature for overall survival prediction and immune infiltration in patients with breast cancer.
    Int J Oncol. 2022;61.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

62. SUNG H, Koka H, Marino N, Pfeiffer RM, et al
    Association of Genetic Ancestry With Terminal Duct Lobular Unit Involution Among Healthy Women.
    J Natl Cancer Inst. 2022;114:1420-1424.
    PubMed         Abstract available
    
    
63. CATHCART-RAKE EJ, Ruddy KJ
    Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?
    J Natl Cancer Inst. 2022;114:1315-1316.
    PubMed        
    
    
64. LEE CI, Elmore JG
    Cancer Risk Prediction Paradigm Shift: Using Artificial Intelligence to Improve Performance and Health Equity.
    J Natl Cancer Inst. 2022;114:1317-1319.
    PubMed        
    
    
65. OESTERREICH S, Nasrazadani A, Zou J, Carleton N, et al
    Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
    J Natl Cancer Inst. 2022 Oct 14. pii: 6758318. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

66. PAWLAK N, Karamchandani M, Wareham C, Gaffney K, et al
    Comparing oncoplastic breast reduction with immediate symmetry surgery to standard breast reduction surgery: Are postoperative complications worse?
    J Surg Oncol. 2022;126:956-961.
    PubMed         Abstract available
    
    
67. WU YOUNG MY, Garza RM, Chang DW
    "Immediate versus delayed autologous breast reconstruction in patients undergoing post-mastectomy radiation therapy: A paradigm shift".
    J Surg Oncol. 2022;126:949-955.
    PubMed         Abstract available
    
    
68. COTLER JH, Nogueira L, McCabe R, Nelson H, et al
    Evaluating information loss in the National Cancer Database from cases lost to follow-up.
    J Surg Oncol. 2022;126:1123-1132.
    PubMed         Abstract available
    
    
69. ZABOROWSKI AM, Roe S, Rothwell J, Evoy D, et al
    A systematic review of oncological outcomes after nipple-sparing mastectomy for breast cancer.
    J Surg Oncol. 2022 Oct 8. doi: 10.1002/jso.27115.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

70. RUGO HS, Singer L
    First, do no harm: risk of secondary cancer after breast cancer treatment.
    Lancet Oncol. 2022 Oct 11. pii: S1470-2045(22)00627.
    PubMed        
    
    
71. VEIGA LHS, Vo JB, Curtis RE, Mille MM, et al
    Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study.
    Lancet Oncol. 2022 Oct 11. pii: S1470-2045(22)00561.
    PubMed         Abstract available
    
    

    
    N Engl J Med

72. SUN R, Wei LJ
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435.
    PubMed        
    
    
73. ALTUNDAG K
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435-1436.
    PubMed        
    
    
74. CORTES J, Zhou X, Schmid P
    Pembrolizumab in Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;387:1436.
    PubMed        
    
    

    
    NPJ Breast Cancer

75. RUGO HS, Brufsky A, Liu X, Li B, et al
    Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
    NPJ Breast Cancer. 2022;8:114.
    PubMed         Abstract available
    
    

    
    PLoS One

76. NAM KE, Kim I, Park HY, Lee JI, et al
    The effect of breast cancer surgery on spine alignment: Whole-spine radiograph analysis.
    PLoS One. 2022;17:e0276173.
    PubMed         Abstract available
    
    
77. DE BONIFACE J, Altena R, Haddad Ringborg C, Bolam KA, et al
    Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial.
    PLoS One. 2022;17:e0274804.
    PubMed         Abstract available
    
    
78. JAGARLAMUDI KK, L S, M Z, J O, et al
    Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples.
    PLoS One. 2022;17:e0275444.
    PubMed         Abstract available
    
    
79. KIBRET YM, Leka YA, Tekle NF, Tigeneh W, et al
    Patterns of cancer in Wolaita Sodo University Hospital: South Ethiopia.
    PLoS One. 2022;17:e0274792.
    PubMed         Abstract available
    
    
80. POKORA RM, Buttner M, Schulz A, Schuster AK, et al
    Determinants of mammography screening participation-a cross-sectional analysis of the German population-based Gutenberg Health Study (GHS).
    PLoS One. 2022;17:e0275525.
    PubMed         Abstract available
    
    

    
    Radiology

81. WOLFSON S, Kim E
    Breast Cancer Screening and Axillary Adenopathy in the Era of COVID-19 Vaccination.
    Radiology. 2022 Oct 11:222040. doi: 10.1148/radiol.222040.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: